Literature DB >> 14529369

Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database.

R H Levy1, H Hachad, C Yao, I Ragueneau-Majlessi.   

Abstract

A comprehensive search of the literature was undertaken using the Metabolism and Transport Drug Interaction Database (http://depts.washington.edu/didbase/) to evaluate the relationship between extent of inhibition and inhibitor dose. The search included reversible and irreversible inhibitors in studies conducted in the period 1966-2003. Only twelve inhibitors met the criterion of the search: study population exposed to more than one dose of inhibitor within a given study design. Six were reversible inhibitors: ciprofloxacin, enoxacin, felbamate, fluconazole, fluvoxamine and ketoconazole. The other six (cimetidine, diltiazem, disulfiram, paroxetine, verapamil and ritonavir) are considered irreversible inhibitors. Most of the AUC/Clearance data available for both types of inhibitors suggested evidence of dose-dependent inhibition. In the case of reversible inhibitors, the evidence of dose-dependent inhibition is consistent with a number of recent studies suggesting the determination of in vivo inhibition constants based on plasma concentration of inhibitor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529369     DOI: 10.2174/1389200033489325

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  3 in total

1.  Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Authors:  Nicolas Hohmann; Antje Blank; Jürgen Burhenne; Yosuke Suzuki; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

2.  Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.

Authors:  I Templeton; C-C Peng; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-08-25       Impact factor: 6.875

3.  Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

Authors:  Chao Zhang; Paolo Denti; Eric Decloedt; Gary Maartens; Mats O Karlsson; Ulrika S H Simonsson; Helen McIlleron
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.